Last reviewed · How we verify
NCT05743348: TELECOVID
COVID-19 e Telepsychotherapy: Which Variables Affect Therapeutic Experience?
trial testing Telepsychotherapy in Telepsychotherapy in 71 participants. Completed in 30 April 2022.
30 April 2022
Quick facts
| Lead sponsor | Istituto Auxologico Italiano |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 71 |
| Start date | 5 April 2021 |
| Primary completion | 30 April 2022 |
| Estimated completion | 30 April 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Telepsychotherapy
Conditions studied
- Telepsychotherapy — all drugs for Telepsychotherapy →
Sponsor
Istituto Auxologico Italiano — full company profile →
Who can join
Adults 18 to 100, any sex, with Telepsychotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
COVID-19 pandemic forced a widespread adoption of telemedicine, including telepsychotherapy. Telepsychotherapy has been proven to be effective before COVID-19 breakout (Poletti et al., 2020); however, both patients and therapists were skeptical about this modality. The aim of this study is to probe the experience of telepsychotherapy in both patients and therapists, during the COVID-19 lockdown. Thus, when the adoption of online colloquia was mandatory and not an option. Crucially, studying the experience of telepsychotherapy during the COVID-19 pandemic allows i) investigating also the experience of those patients and therapists that were not favorable to this kind of intervention and ii) comparing the experience of therapy in the online and face-to-face modality, in the same patients and therapists. Furthermore, we collect several psychological variables that possibly influence the experience and efficacy of telepsychotherapy (e.g., personality traits, attachment state of mind, previous traumatic experiences) to define the psychological profile behind a favorable or negative experience of telemedicine in both patients and therapists. As crucial novelty, this information is collected in both patients and their therapists, allowing the direct comparisons between the experience of the therapeutic relationship (e.g., empathy, alliance) from two different point of views. The results of the present study may help in the definition of possible subgroups of patients who may be sufficiently responsive to telepsychotherapy and those who may benefit - exclusively - of face-to-face interventions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05743348
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Telepsychotherapy
Trials testing the same drug.
- NCT05139433 — Brief Internet-delivered Intervention for Children and Adolescents With Anxiety and Depression Symptoms · NA · completed
Other Istituto Auxologico Italiano trials
Trials by the same sponsor.
- NCT07384962 — ORION Study: Mesh Position and Risk During Subsequent Minimally Invasive Abdominal Surgery · not yet recruiting
- NCT07358832 — Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute Stage of Disease · NA · recruiting
- NCT07302321 — Needs of ALS Patients With C9orf72 Mutation and Their Caregivers · recruiting
- NCT07162740 — Implantable Loop Recorder and Cardioneuroblation · not yet recruiting
- NCT07312240 — LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05743348 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Auxologico Italiano
- Last refreshed: 24 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05743348.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing